Physician profile
Robert B Gerber
NPI 1023059110
$1,048.06
in general payments reported to CMS, 2019-2025
13 companies · $39.80 in 2025
The $39.80 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.35 · 2020: $162 · 2021: $340 · 2022: $179 · 2023: $205 · 2024: $72.94 · 2025: $39.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $318.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $764.08 | 2019-2025 | Nucala, Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $64.69 | 2024-2025 | Uptravi, Opsumit |
| United Therapeutics Corporation | $40.27 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $29.43 | 2020-2021 | |
| Nabriva Therapeutics, Plc | $23.26 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $22.03 | 2021 | |
| Vanda Pharmaceuticals INC. | $17.20 | 2019 | |
| Insmed, INC. | $16.24 | 2020 | |
| Mylan Specialty L.P. | $16.17 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.99 | 2019 | |
| Adma Biomanufacturing LLC | $14.24 | 2021 | |
| Eisai INC. | $13.06 | 2021 | |
| Genzyme Corporation | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gerber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.